Hereditary hemochromatosis

Preview

Hereditary hemochromatosis, once believed to be rare, is now known to affect 1 in 250 to 300 people of northern European descent. Untreated, the disorder can have serious complications, but for patients in whom it is discovered and treated early, the prognosis is good. In this guide to diagnosis and management, Drs Olynyk and Bacon discuss, among other things, which patients to screen, what tests to order, length of treatment, effect of treatment on complications, and prognosis.

Additional information

Notes on contributors

John K. Olynyk

John K. Olynyk, MBBS Bruce R. Bacon, MD Dr Olynyk (right) is senior lecturer in gastroenterology, University of Western Australia, and Dr Bacon (left) is professor of internal medicine and director, division of gastroenterology and hepatology, Saint Louis University School of Medicine.

Bruce R. Bacon

John K. Olynyk, MBBS Bruce R. Bacon, MD Dr Olynyk (right) is senior lecturer in gastroenterology, University of Western Australia, and Dr Bacon (left) is professor of internal medicine and director, division of gastroenterology and hepatology, Saint Louis University School of Medicine.